Results 121 to 130 of about 29,286 (231)
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment
, 2014 SummaryDasatinib may cause various adverse effects such as myelosuppression and pleural effusion. It is well known that dasatinib may affect cellular immunity, which leads to the subsequent risk of a myriad of infections and viral reactivations ...
Chang, Hung +2 more
core +1 more source
Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.Tumour‐intrinsic DRAM1, induced by DNA damage and IFN‐γ, activates an autophagy/JAK‐STAT axis that recruits Tregs, causing CD8+ T cell exhaustion and establishing a self‐sustaining, immunotherapy‐resistant “cold” tumour microenvironment. Abstract Background DNA damage‐regulated autophagy modulator 1 (DRAM1) is a lysosomal protein involved in autophagy ...
Jinchun Wu +7 more
wiley +1 more source
Experience with dasatinib and nilotinib use in pregnancy
, 2017 Pregnancy in a patient with chronic myeloid leukemia presents a therapeutic challenge. Both dasatinib and nilotinib are indicated for first-line treatment as well as for treatment–resistant chronic myeloid leukemia.
Theodora Barkoulas, Philip D Hall
core +1 more source
Food Science &Nutrition, Volume 14, Issue 6, June 2026.Perfluoroheptanoic acid (PFHpA) induces premature senescence in normal human skin fibroblasts (HSFs), as characterized by decreased cell viability, increased SA‐β‐gal staining, impaired wound healing, cell cycle dysregulation, elevated ROS levels, and upregulated SASP mRNA expression.
Jiaqi Fu +7 more
wiley +1 more source
Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations
, 2009 Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Cortes, J. +4 more
core +1 more source
Combination of dasatinib and VPA inhibits HL60 cell proliferation.
, 2014 Cells were stimulated with various concentrations of 0, 0.5, 1, 1.5 and 2 µM dasatinib for 72 hr. The cytotoxicity was then evaluated by an MTS assay. (A) Dose-dependent responses of VPA on cell viability.
Eui-Kyu Noh (576390) +5 more
core +1 more source
Repurposing dasatinib for diffuse large B cell lymphoma
, 2019 To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a library of drugs and other targeted compounds approved by the US Food and Drug Administration on 9 cell lines and validated the results on a panel of 32 genetically ...
Mittan, Sandeep K. +10 more
core +1 more source
Medication adherence for Imatinib, Nilotinib and Dasatinib.
, 2013 Medication adherence for Imatinib, Nilotinib and Dasatinib.
Alberto Costantini (379815) +4 more
core +1 more source